CoChat
Sign Up
Cited by 1,925SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Open access
Cantuti-Castelvetri, Ludovico, Ojha, Ravi, Pedro, Liliana D., Djannatian, Minou, Franz, Jonas, Kuivanen, Suvi, van der Meer, Franziska, Kallio, Katri, Kaya, Tuğberk, Anastasina, Maria, Smura, Teemu, Levanov, Lev, Szirovicza, Leonora, Tobi, Allan, Kallio-Kokko, Hannimari, Österlund, Pamela, Joensuu, Merja, Meunier, Frédéric A., Butcher, Sarah J., Winkler, Martin Sebastian, Mollenhauer, Brit, Helenius, Ari, Gokce, Ozgun, Teesalu, Tambet, Hepojoki, Jussi, Vapalahti, Olli, Stadelmann, Christine, Balistreri, Giuseppe, Simons, Mikael·2020·Science
DOI 10.1126/science.abd2985PMC PMC7857391

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Another host factor for SARS-CoV-2: Virus-host interactions determine cellular entry and spreading in tissues. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the earlier SARS-CoV use angiotensin-converting enzyme 2 (ACE2) as a receptor; however, their tissue tropism differs, raising the possibility that additional host factors are involved. The spike protein of SARS-CoV-2 contains a cleavage site for the protease furin that is absent from SARS-CoV (see the Perspective by Kielian). Cantuti-Castelvetri et al. now show that neuropilin-1 (NRP1), which is known to bind furin-cleaved substrates, potentiates SARS-CoV-2 infectivity. NRP1 is abundantly expressed in the respiratory and olfactory epithelium, with highest expression in endothelial and epithelial cells. Daly et al. found that the furin-cleaved S1 fragment of the spike protein binds directly to cell surface NRP1 and blocking this interaction with a small-molecule inhibitor or monoclonal antibodies reduced viral infection in cell culture. Understanding the role of NRP1 in SARS-CoV-2 infection may suggest potential targets for future antiviral therapeutics. Science , this issue p. 856 , p. 861 ; see also p. 765

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/science.abd2985

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 NRP1 facilitates the cellular entry of SARS-CoV-2 pseudotyped particles. (A) Representative images and quantification of SARS-CoV-2 S protein (SARS-2) (blue bars) and vesicular stomatitis virus glycoprotein (VSV-G) pseudotype (gray bars) infectivity in HEK-293T cells transiently expressing control (ctrl) vector, ACE2, NRP1, or TMPRSS2 (TSS2). Data are normalized to the respective infectivity of SARS-2 and VSV-G pseudotype in ACE2-expressing cells. Two-way analysis of variance (ANOVA) was carried out with Tukey’s correction for multiple comparisons. (B) HEK-293T cells transiently expressing ACE2 and TMPRSS2 or NRP1, ACE2, and TMPRSS2 were inoculated with SARS-2 pseudotype. Data are normalized to SARS-2 infectivity in cells expressing ACE2 and TMPRSS2. One-way ANOVA was performed with Tukey’s correction for multiple comparisons. (C) SARS-2 pseudotype infectivity in Caco-2 cells expressing NRP1 or control vector. Data are normalized to the respective infectivity of SARS-2 and VSV-G pseudotype in control cells. Two-way ANOVA was carried out with Sidak’s correction for multiple comparisons. (D and E) HEK-293T cells transiently expressing NRP1, ACE2, and TMPRSS2 were inoculated with SARS-2 pseudotype in the presence of mAb3 antibody against NRP1 [(D), mAb3] or control mAb2 [(D), ctrl Ab] and in the presence of soluble NRP1 wild-type b1b2 domain [(E), wt b1b2] or NRP1 mutant b1b2 domain [(E), mut b1b2]. Data in (E) are normalized to untreated cells expressing NRP1, ACE2, and TMPRSS2. Two-tailed unpaired Student’s t test was performed. All data are represented as means ± SDs from three independent experiments [(A) to (C)] or three biological replicates [(D) and (E)]. *P < 0.05, **P < 0.01, ****P < 0.0001. All images show GFP-positive, infected cells (magenta) and Hoechst stain (cyan). Scale bars, 100 μm.
Fig. 1 NRP1 facilitates the cellular entry of SARS-CoV-2 pseudotyped particles. (A) Representative images and quantification of SARS-CoV-2 S protein (SARS-2) (blue bars) and vesicular stomatitis virus glycoprotein (VSV-G) pseudotype (gray bars) infectivity in HEK-293T cells transiently expressing control (ctrl) vector, ACE2, NRP1, or TMPRSS2 (TSS2). Data are normalized to the respective infectivity of SARS-2 and VSV-G pseudotype in ACE2-expressing cells. Two-way analysis of variance (ANOVA) was carried out with Tukey’s correction for multiple comparisons. (B) HEK-293T cells transiently expressing ACE2 and TMPRSS2 or NRP1, ACE2, and TMPRSS2 were inoculated with SARS-2 pseudotype. Data are normalized to SARS-2 infectivity in cells expressing ACE2 and TMPRSS2. One-way ANOVA was performed with Tukey’s correction for multiple comparisons. (C) SARS-2 pseudotype infectivity in Caco-2 cells expressing NRP1 or control vector. Data are normalized to the respective infectivity of SARS-2 and VSV-G pseudotype in control cells. Two-way ANOVA was carried out with Sidak’s correction for multiple comparisons. (D and E) HEK-293T cells transiently expressing NRP1, ACE2, and TMPRSS2 were inoculated with SARS-2 pseudotype in the presence of mAb3 antibody against NRP1 [(D), mAb3] or control mAb2 [(D), ctrl Ab] and in the presence of soluble NRP1 wild-type b1b2 domain [(E), wt b1b2] or NRP1 mutant b1b2 domain [(E), mut b1b2]. Data in (E) are normalized to untreated cells expressing NRP1, ACE2, and TMPRSS2. Two-tailed unpaired Student’s t test was performed. All data are represented as means ± SDs from three independent experiments [(A) to (C)] or three biological replicates [(D) and (E)]. *P < 0.05, **P < 0.01, ****P < 0.0001. All images show GFP-positive, infected cells (magenta) and Hoechst stain (cyan). Scale bars, 100 μm.CC BY · PubMed Central
Fig. 2 A blocking antibody against the b1b2 domain of NRP1 reduces infection by wild-type SARS-CoV-2 (SARS-2-wt) but not a mutant with a deletion at the furin-cleavage site (SARS-2-mut). (A) Sequence analysis of viruses isolated at different passages (P) from different cell types. The first sequence is the reference from the Wuhan isolate (NC_045512.2). The sequence abundance in each virus population is indicated as a percentage. ND, not determined. §, SARS-2-wt; §§, SARS-2-mut. A, Ala; S, Ser; Y, Tyr; Q, Gln; T, Thr; N, Asn; P, Pro; R, Arg; V, Val. (B) A deletion adjacent to the furin-cleavage site abrogates the enzymatic cleavage of the S protein. Immunoblot analysis was carried out on cell lysates from Vero-E6 cells infected for 16 hours with two viral populations (§ and §§). Numbers indicate protein size (in kilodaltons). (C and D) Representative images and quantification of SARS-2-wt infectivity in HEK-293T cells stably expressing ACE2 (blue bars) or NRP1 (orange bars) compared with nontransfected cells (gray bars). Different virus titers were used. Data are normalized to the infectivity in ACE2-expressing cells at multiplicity of infection (MOI) = 5. Two-way ANOVA was done with Tukey’s correction for multiple comparisons. (E and F) Representative images (E) and quantification (F) of HEK-293T cells stably expressing the indicated combinations of ACE2, TMPRSS2 (TSS2), and NRP1 after inoculation with SARS-2-wt (wt; blue bars) or SARS-2-mut (mut; gray bars). Data are normalized to the respective infectivity in ACE2-expressing cells. Two-way ANOVA was performed with Tukey’s correction for multiple comparisons. (G and H) Caco-2 cell infection in the presence of control mAb2 (ctrl. Ab) or mAb3 blocking antibodies against NRP1 after SARS-2-wt (wt; blue bars) or SARS-2-mut (mut; gray bars) inoculation. Data are normalized to the respective vehicle control (phosphate-buffered saline) sample. Two-way ANOVA was performed with Tukey’s correction for multiple comparisons. Data are means ± SDs from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Magenta, SARS-2-wt– and SARS-2-mut–infected cells; Hoechst stain, cyan. Scale bars, 50 μm.
Fig. 2 A blocking antibody against the b1b2 domain of NRP1 reduces infection by wild-type SARS-CoV-2 (SARS-2-wt) but not a mutant with a deletion at the furin-cleavage site (SARS-2-mut). (A) Sequence analysis of viruses isolated at different passages (P) from different cell types. The first sequence is the reference from the Wuhan isolate (NC_045512.2). The sequence abundance in each virus population is indicated as a percentage. ND, not determined. §, SARS-2-wt; §§, SARS-2-mut. A, Ala; S, Ser; Y, Tyr; Q, Gln; T, Thr; N, Asn; P, Pro; R, Arg; V, Val. (B) A deletion adjacent to the furin-cleavage site abrogates the enzymatic cleavage of the S protein. Immunoblot analysis was carried out on cell lysates from Vero-E6 cells infected for 16 hours with two viral populations (§ and §§). Numbers indicate protein size (in kilodaltons). (C and D) Representative images and quantification of SARS-2-wt infectivity in HEK-293T cells stably expressing ACE2 (blue bars) or NRP1 (orange bars) compared with nontransfected cells (gray bars). Different virus titers were used. Data are normalized to the infectivity in ACE2-expressing cells at multiplicity of infection (MOI) = 5. Two-way ANOVA was done with Tukey’s correction for multiple comparisons. (E and F) Representative images (E) and quantification (F) of HEK-293T cells stably expressing the indicated combinations of ACE2, TMPRSS2 (TSS2), and NRP1 after inoculation with SARS-2-wt (wt; blue bars) or SARS-2-mut (mut; gray bars). Data are normalized to the respective infectivity in ACE2-expressing cells. Two-way ANOVA was performed with Tukey’s correction for multiple comparisons. (G and H) Caco-2 cell infection in the presence of control mAb2 (ctrl. Ab) or mAb3 blocking antibodies against NRP1 after SARS-2-wt (wt; blue bars) or SARS-2-mut (mut; gray bars) inoculation. Data are normalized to the respective vehicle control (phosphate-buffered saline) sample. Two-way ANOVA was performed with Tukey’s correction for multiple comparisons. Data are means ± SDs from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Magenta, SARS-2-wt– and SARS-2-mut–infected cells; Hoechst stain, cyan. Scale bars, 50 μm.CC BY · PubMed Central
Fig. 3 NRP mediates entry of nanoparticles coated with SARS-CoV-2 (SARS-2) S–derived CendR peptides into cultured cells, olfactory epithelium, and the central nervous system of mice. (A) Peptide sequences used for AgNP coating. The peptides mimic SARS-2 S protein after furin cleavage (post) and as controls; S protein before cleavage (pre), in which the terminal amino acid is replaced by alanine (Ala); or with an amide terminus (post amide). X, any amino acid. The arrow indicates the cleavage site. (B and C) Representative images and quantification of the internalization of peptide-coated AgNPs in HEK-293T cells expressing NRP1. Merged images show AgNP-positive cells (magenta) and Hoechst stain (cyan). One-way ANOVA was carried out with Tukey’s correction for multiple comparisons. (D to G) Representative images and quantification of the main olfactory epithelium [(D) and (E), respectively] and cortex [(F) and (G), respectively] 6 hours after intranasal administration of AgNPs coated with SARS2-post and SARS2-post amide peptides. n = 4 replicates for (C); n = 5 (E) and n = 4 (G) mice per condition. Data are means ± SDs. Two-tailed unpaired Student’s t test; *P < 0.05, ***P < 0.001. Magenta, AgNPs; cyan, Hoechst stain; green, NeuN (neuronal marker); yellow, AQP4. Scale bars, 100 μm (B), 20 μm [(D) and (F)].
Fig. 3 NRP mediates entry of nanoparticles coated with SARS-CoV-2 (SARS-2) S–derived CendR peptides into cultured cells, olfactory epithelium, and the central nervous system of mice. (A) Peptide sequences used for AgNP coating. The peptides mimic SARS-2 S protein after furin cleavage (post) and as controls; S protein before cleavage (pre), in which the terminal amino acid is replaced by alanine (Ala); or with an amide terminus (post amide). X, any amino acid. The arrow indicates the cleavage site. (B and C) Representative images and quantification of the internalization of peptide-coated AgNPs in HEK-293T cells expressing NRP1. Merged images show AgNP-positive cells (magenta) and Hoechst stain (cyan). One-way ANOVA was carried out with Tukey’s correction for multiple comparisons. (D to G) Representative images and quantification of the main olfactory epithelium [(D) and (E), respectively] and cortex [(F) and (G), respectively] 6 hours after intranasal administration of AgNPs coated with SARS2-post and SARS2-post amide peptides. n = 4 replicates for (C); n = 5 (E) and n = 4 (G) mice per condition. Data are means ± SDs. Two-tailed unpaired Student’s t test; *P < 0.05, ***P < 0.001. Magenta, AgNPs; cyan, Hoechst stain; green, NeuN (neuronal marker); yellow, AQP4. Scale bars, 100 μm (B), 20 μm [(D) and (F)].CC BY · PubMed Central
Fig. 4 SARS-CoV-2 infects the olfactory epithelium. (A) Costaining of S protein (brown) and NRP1 (purple) in the apical olfactory epithelium (OE) in a noninfected control (left) and in the apical OE (middle) and adjacent mucosa (right) in a COVID-19 patient. LP, lamina propria; HB, horizontal basal cells. (B) Costaining of NRP1 (magenta) or OLIG-2 (magenta) with S protein (yellow) in OE cells. Nuclei are shown in blue. Scale bars, 10 μm.
Fig. 4 SARS-CoV-2 infects the olfactory epithelium. (A) Costaining of S protein (brown) and NRP1 (purple) in the apical olfactory epithelium (OE) in a noninfected control (left) and in the apical OE (middle) and adjacent mucosa (right) in a COVID-19 patient. LP, lamina propria; HB, horizontal basal cells. (B) Costaining of NRP1 (magenta) or OLIG-2 (magenta) with S protein (yellow) in OE cells. Nuclei are shown in blue. Scale bars, 10 μm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 1

  1. 10.1016/j.cell.2020.02.058 · DOI · Paper page

Cited by

Sorted by citations

See all 1,925

Related

Metadata

Authors
Cantuti-Castelvetri, L., Ojha, R., Pedro, L. D., Djannatian, M., Franz, J., Kuivanen, S., van der Meer, F., Kallio, K., Kaya, T., Anastasina, M., Smura, T., Levanov, L., Szirovicza, L., Tobi, A., Kallio-Kokko, H., Österlund, P., Joensuu, M., Meunier, F. A., Butcher, S. J., Winkler, M. S., Mollenhauer, B., Helenius, A., Gokce, O., Teesalu, T., Hepojoki, J., Vapalahti, O., Stadelmann, C., Balistreri, G., & Simons, M.
Affiliations
  • Institute of Neuronal Cell Biology, Technical University Munich, Munich, Germany.
  • University of Helsinki (FI)
  • German Center for Neurodegenerative Diseases (DE)
  • Universitätsmedizin Göttingen (DE)
  • Department of Neuropathology, University Medical Center Göttingen, Göttingen, Germany.
  • Department of Virology, Medicum, University of Helsinki, Helsinki, Finland.
  • University of Tartu (EE)
  • Department of Virology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Finnish Institute for Health and Welfare (FI)
  • The University of Queensland (AU)
  • ETH Zurich (CH)
  • Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • University of Zurich (CH)
Corresponding author
  • Ojha, Ravi
  • Pedro, Liliana D.
  • Djannatian, Minou
  • Franz, Jonas
  • Kuivanen, Suvi
  • Balistreri, Giuseppe
  • Simons, Mikael
ORCID
Venue
Science
Publisher
American Association for the Advancement of Science (AAAS)
Published
2020-11-13
Volume
370
Issue
6518
Pages
856-860
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
DOI
10.1126/science.abd2985
PMC
PMC7857391
OpenAlex
W3093867667
Cited by
1,925
References
47
Citations by year
2026: 56 · 2025: 120 · 2024: 211 · 2023: 277 · 2022: 461 · 2021: 669 · 2020: 128
FWCI
50.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Science (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, other-oa)
Funders
ERC CoV
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords
neuropilin-1, SARS-CoV-2, viral entry, furin cleavage, spike protein, host factors, viral infectivity, monoclonal antibodies, small molecule inhibitors, antiviral agents, viral tropism, ACE2
MeSH terms
Protein Domains, Betacoronavirus, Host Microbial Interactions, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, Animals, Antibodies, Monoclonal, Female, Humans, Peptidyl-Dipeptidase A, Lung, Male, Mice, Inbred C57BL, Mutation, Olfactory Mucosa, Peptide Fragments, Pneumonia, Viral, Protein Binding, Serine Endopeptidases, Coronavirus Infections, Caco-2 Cells, Respiratory Mucosa, Neuropilin-1, Neuropilin-2, Mice, Virus Internalization, Metal Nanoparticles, HEK293 Cells, Pandemics, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review